A Phase 3 Study of Enarodustat (JTZ-951) in Japanese Hemodialysis Patients for Treatment of Anemia in Chronic Kidney Disease: SYMPHONY HD Study

• Main Authors: Tadao Akizawa (Author), Masaomi Nangaku (Author), Takuhiro Yamaguchi (Author), Ryosuke Koretomo (Author), Kazuo Maeda (Author), Yuya Miyazawa (Author), Hideki Hirakata (Author)
• Format: Book
• Published: Karger Publishers, 2021-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Introduction: Enarodustat (JTZ-951) is a new oral hypoxia-inducible factor-prolyl hydroxylase inhibitor for the treatment of anemia in chronic kidney disease (CKD). We conducted a phase 3 study to compare the efficacy and safety of enarodustat with darbepoetin alfa (DA) in Japanese anemic patients w...